GlassScriptPhysician profile
Arielle S Silver
NPI 1083623763
$2,205.16
in general payments reported to CMS, 2019-2025
14 companies · $651 in 2025
The $651 reported for 2025 was less than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $161 · 2020: $54.96 · 2021: $258 · 2022: $116 · 2023: $243 · 2024: $720 · 2025: $651.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,570 · Education: $45.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,569.96 |
| Education | $45.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,193.85 | 2019-2025 | Rinvoq, Humira, Skyrizi |
| Amgen INC. | $371.90 | 2020-2025 | Krystexxa, Evenity, Prolia |
| Janssen Biotech, INC. | $206.43 | 2020-2025 | Tremfya |
| Novartis Pharmaceuticals Corporation | $108.75 | 2025 | |
| Ucb, INC. | $98.55 | 2020-2025 | Bimzelx |
| Astrazeneca Pharmaceuticals LP | $64.03 | 2024-2025 | Saphnelo |
| Genentech USA, INC. | $45.31 | 2019-2022 | |
| Depuy Synthes Sales INC. | $27.15 | 2019 | |
| Horizon Therapeutics Plc | $22.53 | 2023 | Krystexxa |
| E.R. Squibb & Sons, L.L.C. | $18.92 | 2025 | Orencia |
| Organon LLC | $18.02 | 2025 | Hadlima |
| Pfizer INC. | $16.15 | 2021 | |
| Glaxosmithkline, LLC. | $13.57 | 2024 | Benlysta |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arielle Silver listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.